Hereditary Angioedema is a rare genetic condition that causes unpredictable episodes of swelling — often of the hands, feet, face, throat, or abdomen. Throat swelling can be life-threatening. Abdominal attacks cause severe pain frequently mistaken for a surgical emergency. HAE does not respond to antihistamines or steroids, but modern targeted treatments now exist that may substantially reduce attack frequency and severity for appropriately selected patients. Individual response varies.
Hereditary Angioedema is a genetic disorder of the complement and contact activation systems. Most patients have a deficiency or dysfunction of C1 esterase inhibitor — a protein that regulates production of bradykinin. When the regulation fails, bradykinin accumulates locally and causes the blood vessels to leak, producing the characteristic swelling.
Because HAE is bradykinin-mediated rather than histamine-mediated, it does not respond to the medications used for typical allergic swelling. Antihistamines, steroids, and epinephrine — the standard treatments for ordinary angioedema or anaphylaxis — have little or no effect. The right diagnosis matters enormously because the right treatment is entirely different.
HAE attacks can affect the skin, the gut, and the airway. Throat involvement is potentially fatal and is the reason every patient with HAE needs both an effective acute treatment plan and, for most, a long-term prevention plan.
Diagnosis begins with three blood tests: serum C4 (typically low in Type I and II HAE both during and between attacks), C1-inhibitor quantitative level, and C1-inhibitor functional assay. When indicated, genetic testing is added. A small subset of patients have HAE with normal C1-inhibitor; in these cases, additional genetic testing for FXII, plasminogen, angiopoietin-1, and other identified mutations is considered.
Family history is taken in detail, both to support the diagnosis and to identify other family members who may need testing.
Optimed Immunology prescribes the full range of FDA-approved HAE therapies. Each patient receives an individualized plan that includes both an acute (on-demand) treatment for breakthrough attacks and, in most cases, a long-term prophylactic therapy to prevent attacks.
Acute treatment options include intravenous C1-inhibitor (Berinert, Ruconest), subcutaneous icatibant (Firazyr and other brands), provider-administered ecallantide (Kalbitor), and the first oral on-demand option, sebetralstat (Ekterly). Long-term prophylaxis options include subcutaneous lanadelumab (Takhzyro), subcutaneous garadacimab once monthly (Andembry), subcutaneous donidalorsen every 4–8 weeks (Dawnzera), subcutaneous C1-inhibitor (Haegarda), intravenous C1-inhibitor (Cinryze), and oral berotralstat (Orladeyo). The right combination depends on attack pattern, severity, route preference, and lifestyle.
All prior authorizations are handled in-house. Patients receive a written action plan and education on early recognition and treatment of attacks.
A first visit for suspected or known HAE lasts 60 minutes or longer. Dr. McNeil reviews your complete attack history, family history, and prior treatment trials. Diagnostic labs are ordered if not already complete. For confirmed HAE, the visit also covers building an acute treatment plan, considering long-term prophylaxis, and educating you on recognition of throat involvement and when to seek emergency care.
Every patient’s situation is different, but the decision logic for HAE generally follows these steps. This is not a script — it is a structure that gets adapted to each patient’s history, findings, and goals.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes and does not substitute for clinical judgment or direct medical advice. Treatment decisions are individualized based on your full history, examination, and laboratory findings. If you have an emergency, call 911.